Marrone Bio Innovations, Inc. (NASDAQ:MBII) saw strong trading volume on Tuesday . 78,300 shares changed hands during trading, a decline of 5% from the previous session’s volume of 82,510 shares.The stock last traded at $0.94 and had previously closed at $0.93.
Several equities analysts have commented on the company. ValuEngine lowered Marrone Bio Innovations from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th. HC Wainwright set a $4.00 price objective on Marrone Bio Innovations and gave the company a “buy” rating in a research report on Tuesday, August 15th. Finally, Piper Jaffray Companies set a $1.00 price objective on Marrone Bio Innovations and gave the company a “hold” rating in a research report on Saturday, July 22nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. Marrone Bio Innovations presently has an average rating of “Hold” and a consensus target price of $2.50.
The company has a quick ratio of 0.98, a current ratio of 1.37 and a debt-to-equity ratio of -1.63.
Marrone Bio Innovations (NASDAQ:MBII) last announced its quarterly earnings data on Monday, August 14th. The basic materials company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). The business had revenue of $6.48 million during the quarter, compared to analyst estimates of $6.62 million. equities research analysts forecast that Marrone Bio Innovations, Inc. will post -1.05 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Marrone Bio Innovations stock. Ardsley Advisory Partners grew its stake in shares of Marrone Bio Innovations, Inc. (NASDAQ:MBII) by 375.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,681,580 shares of the basic materials company’s stock after acquiring an additional 2,907,142 shares during the quarter. Ardsley Advisory Partners owned about 11.74% of Marrone Bio Innovations worth $4,528,000 as of its most recent SEC filing. 38.93% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Marrone Bio Innovations, Inc. (MBII) Sees Unusually-High Trading Volume” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/11/14/marrone-bio-innovations-inc-mbii-sees-unusually-high-trading-volume.html.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.
Receive News & Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related companies with MarketBeat.com's FREE daily email newsletter.